Shopping Cart 0
Cart Subtotal
AED 0

Brazil Pharmaceuticals Market Outlook to 2025 - By International and Domestic Companies, By Retail and Institutional Sales, By Institutional Sales (Public, Private and Others), By Drug Type (Prescription, Over-The-Counter and Generics), By Generic Drug Type (Branded and Local), By Region (Southeast, South, Northeast, Midwest and North), By Therapeutic Areas

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option : Yes
Copy Option : Yes
Deliverable Format : Excel Via Email

Excel Only
AED 11010

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 12845

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: Excel: Yes/ PDF: No
Deliverable Format : Excel, PDF Via Email

Single and Excel
AED 14680

Access to Printed Report; No Soft Copy
Print Option: N/A
Copy Option: N/A
Deliverable Format : Printed Publication/ Book by Post

Hard Copy License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 16515

Details

The report titled “Brazil Pharmaceuticals Market Outlook to 2025 - By International and Domestic Companies, By Retail and Institutional Sales, By Institutional Sales (Public, Private and Others), By Drug Type (Prescription, Over-The-Counter and Generics), By Generic Drug Type (Branded and Local), By Region (Southeast, South, Northeast, Midwest and North), By Therapeutic Areas” provides a comprehensive analysis of the Pharmaceuticals market in Brazil. The report also covers the overview and genesis, market size in terms of Revenue, trends and developments, issues and challenges and regulations in Brazil. The report provides value chain, competitive scenario and company profiles of the major players operating in Brazil. The report concludes with market projection and analyst recommendations highlighting the major opportunities and cautions.


Brazil Pharmaceuticals Market Overview and Size
Brazil Pharmaceuticals market in terms of revenue increased at a double digit CAGR during the review period 2013-2018. The market was observed to be at growth stage owing to growing intensity of competition among the domestic and international manufacturers in the market which allows them to invest heavily in Research and Development and provides wide offering of patented and generic drugs in Prescription and Over-The-Counter form in the country. In Brazil, the number of growing chronic diseases and per capita healthcare expenditure to spend on the medications will improve the revenues of Pharmaceuticals Market over the years in Brazil.
The market is booming with the Universal Health System, growing elderly population, huge investment in R&D for new drugs, reduced time in the manufacturing approval process, increasing government health expenditure, acquisitions of brands to expand in different regions and segments coupled with per capita income of individuals in Brazil.

Brazil Pharmaceuticals Market Segmentation

By International and Domestic Companies: Brazil is moderately fragmented market with the presence of many International and Domestic players. International Companies dominates the sales volume of patented drugs whereas the domestic companies are largely involved in the production of Generic drugs in terms of sales volume. On the other hand, patented drugs are largely expensive and generate comparatively higher revenues than the generics. Moreover, International companies have strong distribution channel to serve every region in Brazil. Hence, they accounts for a larger share in terms of revenue in Pharmaceuticals Market in Brazil.

By Distribution Channel: Majority of the revenues are generated from the retail segment in Brazil. The highest revenue share of retail sales was largely due to the presence of number of retail outlets in all the areas of Brazil. Institutional sales on the other hand are driven by the new product innovations being largely recommended by physician or the doctor.

By Institutional Sales: Public Institutions in Brazil accounted for the highest percentage share in terms of revenue due to the presence of large number of public hospitals in the country and the Hospitals’ own pharmacies that gives the advantage of prescription and OTC medications to the patients. Private Institutions on the other hand accounted for a lower percentage share due to the decline in the number of private hospitals observed over the years.

By Type of Drugs: Prescription drugs accounted for the highest revenue share in terms in the year 2018. Prescription drugs in the market are generally patented drugs being recommended by the doctors and are usually taken for chronic diseases. These medicines are being served among middle to upper class population in Brazil. Higher prices of these medicines generate higher revenues from prescription drugs segment in the country. OTC and Generic drugs on the other hand are affordable by the majority of the population and serve the underpenetrated areas of the country.

By Region: Southeast region in Brazil that includes Sao Paulo and Rio de Janeiro accounted for highest revenue share in 2018 due to the highest population in Brazil, Highest contribution to GDP, diverse pharmaceutical industry and high purchasing power of in that region. Southeast region is followed by South and Midwest region in Brazil due to the high purchasing power of the individuals in that region.

By Therapeutic Areas: Cardiovascular segment accounts for the highest percentage share in terms of revenue in Brazil largely due the highest number of deaths being caused by Ischemic Heart Disease among all other causes of deaths in Brazil. It is followed by Central Nervous System, Respiratory and Oncology. The manufacturing companies are making oncology as their major product innovation area in Brazil.

Competitive Landscape
Pharmaceuticals Market in Brazil is a moderately fragmented market with presence of domestic and international players wherein the patented drug manufacturers are mainly the international companies and generic drug manufacturers are majorly the domestic ones. Major Domestic Companies include Ache Laboratories, EMS Pharma, Eurofarma and Hypera Pharma and international companies include Novartis, Sanofi, Bayer, Abbott Laboratories and many others.

Brazil Pharmaceuticals Market Future Outlook
In future, it is anticipated that the revenue of Pharmaceuticals Market in Brazil will be driven by the growing elderly population (above 65 years), growing prevalent of chronic diseases, increasing per Capita health expenditure, ease in availability of medicines coupled with growing number of acquisitions to expand business portfolio, increasing number of Point of Sale and rising investment in R&D activities.
Key Segments Covered
By Type of Companies
·         International Companies
·         Domestic Companies
By Type of Channel
·         Institutional
Ø  Public
Ø  Private
Ø  Others
·          Retail
By Drug Type
·         Prescription
·         Over-The-Counter
·         Generics
Ø  Branded
Ø  Local
By Region
·         Southeast
·         South
·         Midwest
·         Northeast
·         North
By Therapeutic Areas
·         Cardiovascular
·         Central Nervous System
·         Respiratory
·         Oncology
·         Anti-Infective
·         Gastrointestinal
·         Others
Key Target Audience
·         Pharmaceutical Manufacturing Companies
·         Pharmacy Retail Outlets
·         Government/ Regulatory Authorities
·         Venture Capitalist Firms
·         Health Insurance Companies
·         Pharmaceutical Products Distributors
Time Period Captured in the Report:
·         Historical Period: 2013-2018
·         Forecast Period: 2019F-2025F
Companies Covered:
Major Manufacturers
  • Ache Laboratories
  • EMS Pharma
  • Eurofarma
  • Sanofi
  • Novartis
  • Neo Quimica
  • Mantecopr Farmasa
  • Libbs
  • Biolab- Sanus Farma
  • Takeda Pharma
  • Medley
  • Bayer Pharma
  • CIMED
Key Topics Covered in the Report
·         Brazil Pharmaceuticals Market Overview and Genesis (Overview and Genesis, Business Cycle Graph)
·         Brazil Pharmaceutical Market Value Chain Analysis
·         Brazil Pharmaceutical Market Size
·         Brazil Pharmaceuticals Market Segmentation
·         Regulatory Landscape in Brazil Pharmaceuticals Market
·         Trends and Developments in Brazil Pharmaceuticals Market
·         Issues and Challenges in Brazil Pharmaceuticals Market
·         Brazil Pharmaceuticals Market Competition Landscape
·         Cross Comparison of 7 Major Players in Brazil Pharmaceuticals Market
·         Brazil Pharmaceuticals Market Future Projection, 2018-2025F
·         Future Outlook of Brazil Pharmaceuticals Market Segmentations, 2018-2025F
READ MORE

Table Of Content

Scope

1.     Executive Summary
2.     Research Methodology
2.1.      Market Definitions
2.2.      Abbreviations
2.3.      Market Sizing and Modeling
Consolidated Research Approach
Market Sizing Approach – Brazil Pharmaceuticals Market
Sample Size Inclusion Table
Variables Dependent And Independent
Multi Factor Based Sensitivity Model
Limitations
Final Conclusion
3.     Brazil Pharmaceuticals Market Overview and Genesis
4.     Brazil Pharmaceuticals Market Value Chain Analysis
5.     Brazil Pharmaceuticals Market Size, 2013-2018
5.1.      By Revenue, 2013-2018
6.     Brazil Pharmaceuticals Market Segmentation, 2013 and 2018
6.1.      By International and Domestic Companies, 2013 and 2018
6.2.      By Retail and Institutional, 2013-2018
6.2.1.     By Institutional (Public, Private and Others)
6.2.2.     By Drug Type (Prescription, Over-The-Counter and Generic Drugs), 2018
By Generic Drugs (Branded and Local), 2018
6.2.3.     By Region (Southeast, South, Northeast, Midwest and North), 2018
6.2.4.     By Therapeutic Areas (Cardiovascular, Central Nervous System, Respiratory, Oncology, Anti- Infective, Gastrointestinal and Others), 2018
7.     Brazil Pharmaceuticals Vitamins and Dietary Supplements
8.     Regulatory Landscape in Brazil Pharmaceuticals Market
8.1.      ANVISA (Regulatory Body)
8.2.      Brazil Pharmaceuticals Market Clinical Process
9.     Trends and Developments in Brazil Pharmaceuticals Market
Growing Number of Substitutes for Patented Drugs
Growing Number of mergers and Acquisitions
Government Initiatives to Promote Local Production
Growing Ministry of Health Budget
10.      Issues and Challenges in Brazil Pharmaceuticals Market
Intensified Competition in Local Drug Manufacturers
Economic Instability
Currency Depreciation
11.      SWOT Analysis of Brazil Pharmaceuticals Market
12.      Competitive Landscape in Brazil Pharmaceuticals Market
12.1.    Strengths and Weaknesses of Major Players in Brazil Pharmaceuticals Market
12.2.    Market Share of Major Players (Ache Laboratories, EMS Pharma, Eurofarma, Sanofi, Novartis, Neo Quimica, Mantecorp Farmasa, Libbs, Biolab- Sanus Farma, Takeda Pharma, Medley, Bayer Pharma, CIMED, Pfizer and Others) Operating in Brazil Pharmaceuticals Market, 2018
12.3.    Cross-Comparison of 7 Major Players (Year of Establishment, Location, Employee Size, International/Domestic, Business Model and Business Segment, Subsidiaries, Major Specialization, Number of Therapeutic Class and Major Therapeutic Class)
12.4.    Heat Map Analysis of Top 14 Players (Novartis, EMS Pharma, Sanofi, Roche Laboratories, Ache Laboratories, Eurofarma, Bayer, Takeda, Pfizer, Biolab, GSK Pharma, Abbott Laboratories, Janssen Pharmaceuticals and Neo-Quimica) on Regional Presence (Southeast South, Northeast, Mid West, North), 2018
12.5.    Heat Map Analysis of Top 13 Players (Novartis, EMS Pharma, Sanofi, Roche Laboratories, Ache Laboratories, Eurofarma, Bayer, Takeda, Pfizer, Biolab, GSK Pharma, Abbott Laboratories and Janssen Pharmaceuticals) on the Basis of Therapeutic Areas (Gastrointestinal, Cardiology, Anti-Infective, Respiratory, Central Nervous System and Dermatology, Orthopedics, Oncology, Genitourinary and Sex Hormones, Blood Forming Organs/Hematology), 2018
13.      Company Profile of Major Players (Company Overview, Research and Development, Future Outlook, Manufacturing Plants and Production Matrix)
13.1.    Novartis
13.2.    EMS Pharma
13.3.    Hypera Pharma
13.4.    Sanofi Brazil
13.5.    Bayer
13.6.    Roche Laboratories
13.7.    Ache Laboratories
13.8.    Eurofarma
13.9.    Others (Biolab Pharma, Takeda, Cimed)
14.      Brazil Pharmaceuticals Market Future Outlook and Projections, 2018-2025F
14.1.    By Revenue, 2018-2025F
15.      Brazil Pharmaceuticals Market Segmentation Future Outlook and Projections
15.1.    By International and Domestic Companies, 2018-2025F
15.2.    By Retail and Institutional, 2018-2025F
15.2.1.       By Institutional Sales (Public, Private and Others), 2018-2025F
15.2.2.       By Drug Type (Prescription, Over-The-Counter and Generics)
By Generic Drugs (Branded and Local), 2018-2025F
15.2.3.       By Therapeutic Areas (Cardiology, Central Nervous System, Respiratory, Oncology, Anti- Infective, Gastrointestinal and Others), 2025F
16.      Analyst Recommendation
Investment in R&D
Focus on Improving Productivity
Keeping Track of Expiry Patents
Focus on building a strong product portfolio
Inestment in Marketing Activities
Disclaimer
Contact Us


List Of Figure

Figure 1‑1: Brazil Pharmaceuticals Market Flowchart on the Basis of Revenue in USD Billion, 2018
Figure 1‑2: Brazil Pharmaceuticals Market Flowchart on the Basis of Revenue in USD Billion, 2025F
Figure 3‑1: Brazil Pharmaceuticals Industry Life Cycle
Figure 4‑1: Value Chain of Brazil Pharmaceuticals Market
Figure 5‑1: Brazil Pharmaceuticals Market Size of on the Basis of Revenue in USD Billion and Growth Rate in Percentage (%), 2013-2018
Figure 6‑1: Brazil Pharmaceuticals Market Segmentation by Type of Companies (International and Domestic) on the Basis of Revenue in Percentage (%), 2013 and 2018
Figure 6‑2: Brazil Pharmaceuticals Market Segmentation by Retail and Institutional on the Basis of Revenue in Percentage (%), 2013-2018
Figure 6‑3: Brazil Pharmaceuticals Market Segmentation by Institutional (Public, Private and Others) on the Basis of Revenue in Percentage (%), 2013-2018
Figure 6‑4: Number of Hospitals in Brazil by Type (Public and Private), 2013-2018
Figure 6‑5: Brazil Pharmaceuticals Market Segmentation by Drugs (Prescription, Over-The-Counter and Generics) on the Basis of Revenue in Percentage (%), 2018
Figure 6‑6: Brazil Pharmaceuticals Market Segmentation by Type of Generic Drugs (Branded and Local) on the Basis of Revenue in Percentage (%), 2018
Figure 6‑7: Brazil Pharmaceuticals Market Segmentation by Regions (Southeast, South, Northeast, Midwest and North) on the Basis of Revenue in Percentage (%), 2018
Figure 6‑8: Brazil Pharmaceuticals Market Segmentation by Therapeutic Areas (Cardiovascular, Central Nervous System, Respiratory, Oncology, Anti-Infective, Gastrointestinal and Others) on the Basis of Revenue in Percentage (%), 2018
Figure 7‑1: Brazil Vitamins and Dietary Supplements Market Segmentation by Outlet Type (Store-Based Retailing and Non-Store Retailing) on the Basis of Revenue in Percentage (%), 2013-2019P
Figure 7‑2: Brazil Vitamins and Dietary Supplements Market Segmentation by Type (Herbal/Traditional and Standard) on the Basis of Revenue in Percentage (%), 2013-2019P
Figure 8‑1: Clinical Process in Brazil Pharmaceuticals Market
Figure 9‑1: Brazil Pharmaceuticals Market Major Acquisitions on the Basis of Number and Total Deal Value in USD Million, 2007-2016
Figure 9‑2: Ministry of Health Budget in Brazil Including Pharmaceuticals Assistance Activities and Other Ministry of Health Activities in Percentage (%), 2012-2019P
Figure 10‑1: Exchange Rate (BRL-USD), 2013-2018
Figure 12‑1: Market Share of Major Players (Ache Laboratories, EMS Pharma, Eurofarma, Sanofi, Novartis, Neo Quimica, Mantecorp Farmasa, Libbs, Biolab- Sanus Farma, Takeda Pharma, Medley, Bayer Pharma, CIMED, Pfizer and Others) in Brazil Pharmaceuticals Market on the Basis of Revenue in Percentage (%), 2018
Figure 13‑1: Financial Performance of Novartis Group by Business Divisions (Sandoz, Innovative Medicines and Alcon) and by Regions (Europe, United States, Asia, Africa, Australasia, and Canada & Latin America) on the Basis of Revenue in Percentage(%), 2018
Figure 13‑2: Timeline of Hypera Pharma from 2007 to 2017
Figure 13‑3: Distribution Channel of Hypera Pharma including Direct Channel and Indirect Channel on the Basis of Revenue in Percentage (%), 2018(P)
Figure 13‑4: Financial Performance of Hypera Pharma by Business Segments (RX/OTX, Consumer Health, Generics and Dermocosmetics) on the Basis of Revenue in Percentage (%), 2018(P)
Figure 13‑5: Financial Performance of Hypera Pharma by Therapeutic Areas (RX and Dermocosmetics) on the Basis of Revenue in Percentage (%), 2018(P)
Figure 13‑6: Financial Performance of Hypera Pharma by Therapeutic Areas in Consumer Health (Gastrointestinal, Flu and Cold, Vitamins and Nutraceuticals, Pain and Fever, Orthopedics and Others) on the Basis of Revenue in Percentage (%), 2018(P)
Figure 13‑7: Hypera Pharma Products under Pipeline by Business Segments (Prescription Products, Similar & Generics and Consumer Health) on the Basis of Number of Patents in Percentage (%), 2018
Figure 13‑8: Hypera Pharma Products under Pipeline by Innovation (White Spaces, New Technologies, New Formulation and Patented) in Percentage (%), 2018
Figure 13‑9: Hypera Pharma Prescription Products under Pipeline by Therapeutic Areas (General Physician, Central Nervous System, Pain/Pain Killers, Allergy/ Respiratory/ Ear, Cardiovascular & Endocrinology, Gastro Intestinal and Dermocosmetics) in Percentage (%), 2018
Figure 13‑10: Financial Performance of Hypera Pharma on the Basis of Revenue in USD Million, 2015-2018(P)
Figure 13‑11: Financial Performance of Hypera Pharma on the Basis of EBITDA in USD Million, 2015-2018(P)
Figure 13‑12: Financial Performance of Hypera Pharma on the Basis of Gross Profit in USD Million, 2015-2018(P)
Figure 13‑13: Timeline of Sanofi Brazil from 1919 to 2017
Figure 13‑14: Financial Performance of Sanofi in Brazil on the Basis of Revenue in USD Million, 2017-2018
Figure 13‑15: Financial Performance of Bayer in Latin America by Countries (Brazil and Others) on the Basis of Revenue in Percentage (%), 2017 and 2018
Figure 13‑16: Financial Performance of Roche Laboratories on the Basis of Revenue in USD Million, 2017-2018
Figure 13‑17: Ache Laboratories products under pipeline by Franchise (Prescription, Dermatology, OTC, Generics and Specialty Care) on the Basis of Number of Patents, 2013-2022
Figure 13‑18: Financial Performance of Ache Laboratories on the Basis of Revenue in USD Million, 2017-2018
Figure 13‑19: Financial Performance of Ache Laboratories by Therapeutic Areas (Breathing Apparatus, Nervous System, Cardiovascular, Digestive Track and Metabolism, Musculoskeletal System, Endocrine System including Sex Hormones, Dermatology, Genitourinary Systems and Others) on the Basis of Revenue in Percentage (%), 2018
Figure 13‑20: Timeline of Ache Laboratories from the Year 1966 to 2018
Figure 13‑21: Financial Performance of Eurofarma on the Basis of Revenue in USD Million, 2016 and 2017
Figure 13‑22: Financial Performance of Eurofarma on the Basis of Gross Profit in USD Million, 2016 and 2017
Figure 13‑23: Financial Performance of Eurofarma on the Basis of EBITDA in USD Million, 2016 and 2017
Figure 13‑24: Financial Performance of Eurofarma by Segment on the Basis of Revenue in Percentage (%), 2017
Figure 13‑25: Timeline of Eurofarma Laboratories Brazil from 1972 to 2018
Figure 14‑1: Brazil Pharmaceuticals Future Projections on the Basis of Revenue in USD Billion and Growth Rate in Percentage (%), 2018-2025F
Figure 15‑1: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by International and Domestic Companies on the Basis of Revenue in Percentage (%), 2018-2025F
Figure 15‑2: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by Retail and Institutional Sales on the Basis of Revenue in Percentage (%), 2018-2025F
Figure 15‑3: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by Institutional Sales (Public, Private and Others) on the Basis of Revenue in Percentage (%), 2018-2025F
Figure 15‑4: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by Drug Type (Prescription, Over-The-Counter and Generics) on the Basis of Revenue in Percentage (%), 2018-2025F
Figure 15‑5: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by Generic Drugs (Branded and Local) on the Basis of Revenue in Percentage (%), 2018-2025F
Figure 15‑6: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by Therapeutic Areas (Cardiology, Central Nervous System, Respiratory, Oncology, Anti- Infective, Gastrointestinal and Others) on the Basis of Revenue in Percentage (%), 2025F


List Of Table

Table 2‑1: Consolidated Research Approach for Sample Market
Table 2‑2: Sample Size Including Major Players in Brazil Pharmaceuticals Market and Industry Experts
Table 2‑3: Sample Size Inclusion Table Including Respondent Category and Percentage of Sample Size
Table 2‑4: Tentative Set of Questions Asked by Mode of Entities and Desired Outcome
Table 2‑5: Correlation Matrix of Brazil Pharmaceuticals Market
Table 2‑6: Regression Coefficients Outputs of Brazil Pharmaceuticals Market
Table 5‑1: List of Countries Including Number of Patents, 2017
Table 6‑1: Cross Comparison of International and Domestic Companies on the Basis of Revenue Share in terms of Percentage, Major Companies, Regional Presence, Key Focus Area, Specialization, Number of Companies and Growth Drivers
Table 6‑2: Brazil Pharmaceuticals Market Segmentation by Type of Companies (International and Domestic) on the Basis of Revenue in USD Billion, 2013 and 2018
Table 6‑3: Cross Comparison of Retail and Institutional on the Basis of Revenue Share in terms of Percentage (%), Profit Margin, Growth Drivers, Target Audience and Major Drugs
Table 6‑4: Brazil Pharmaceuticals Market Segmentation by Retail and Institutional on the Basis of Revenue in USD Billion, 2013-2018
Table 6‑5: Brazil Pharmaceuticals Market Segmentation by Institutional (Public, Private and Others) on the Basis of Revenue in USD Billion, 2013-2018
Table 6‑6: Number of Hospitals in Brazil by Type (Public and Private), 2013-2018
Table 6‑7: Cross Comparison of Prescription, Over-The-Counter and Generic Drugs on the Basis of Revenue Share in terms of Percentage, Major Companies, Rationale, Target Audience, R&D Costs and Price Difference
Table 6‑8: Brazil Pharmaceuticals Market Segmentation by Drugs (Prescription, Over-The-Counter and Generics) on the Basis of Revenue in USD Billion, 2018
Table 6‑9: Brazil Pharmaceuticals Market Segmentation by Type of Generic Drugs (Branded and Local) on the Basis of Revenue in USD Billion, 2018
Table 6‑10: Cross Comparison by Regions (Southeast, South, Northeast, Midwest and North) including Population, Market Share, Major Cities, Concentration of Companies, GDP Contribution, Economy, Key Performance Indicators and Major Companies
Table 6‑11: Brazil Pharmaceuticals Market Segmentation by Regions (Southeast, South, Northeast, Midwest and North) on the Basis of Revenue in USD Billion, 2018
Table 6‑12: Brazil Pharmaceuticals Market Segmentation by Therapeutic Areas (Cardiovascular, Central Nervous System, Respiratory, Oncology, Anti-Infective, Gastrointestinal and Others) on the Basis of Revenue in USD Billion, 2018
Table 6‑13: Brazil Pharmaceuticals Market Segmentation by Therapeutic Areas (Cardiovascular, Central Nervous System, Respiratory, Oncology, Anti-Infective, Gastrointestinal and Others) on the Basis of Best Selling Medicines, Major Companies and OTC/ Prescribed
Table 7‑1: Brazil Vitamins and Dietary Supplements Snapshot including Market Size, Competition Scenario, Trends and Developments and Major Brands, 2013-2018
Table 7‑2: Brazil Vitamins and Dietary Supplements Market Size on the Basis of Revenue in USD Million and Growth Rate in Percentage (%), 2013-2024F
Table 7‑3: Market Share of Major Players operating in Brazil Vitamins and Dietary Supplements Market on the Basis of Revenue in Percentage (%), 2013-2019P
Table 7‑4: Market Share of Major Players operating in Brazil Vitamins and Dietary Supplements Market on the Basis of Revenue in USD Million, 2013-2019P
Table 7‑5: Market Share of Major Brands Including Major Companies operating in Brazil Vitamins and Dietary Supplements Market on the Basis of Revenue in Percentage (%), 2013-2019P
Table 7‑6: Market Share of Major Brands Including Major Companies operating in Brazil Vitamins and Dietary Supplements Market on the Basis of Revenue in USD Million, 2013-2019P
Table 7‑7: Brazil Vitamins and Dietary Supplements Market Segmentation by Outlet Type (Store-Based Retailing and Non-Store Retailing) on the Basis of Revenue in USD Million, 2013-2019P
Table 7‑8: Brazil Vitamins and Dietary Supplements Market Segmentation by Type (Herbal/Traditional and Standard) on the Basis of Revenue in USD Million, 2013-2019P
Table 8‑1: Government Regulations in Brazil Pharmaceutical Market Including Regulatory Submission of Drug Application, Pricing, Requirements for Price Approval, Access to Drugs, Operating Authorization, Operating License, Product Registration, Technical Responsibility Certificate, Pharmacovigilance, Techno vigilance, Promotion and Marketing and Pre-Conditions for Distribution, 2018
Table 8‑2: Registration and Licensing Requirements in Pharmaceuticals Market in Brazil
Table 9‑1: Major Acquisitions in Brazil Pharmaceuticals Market, 2012-2018
Table 9‑2: Ministry of Health Budget in Brazil Including Pharmaceuticals Assistance Activities and Other Ministry of Health Activities in USD Million, 2012-2019P
Table 9‑3: Pharmaceuticals Assistance Budget in Brazil in USD Million, 2012-2019P
Table 11‑1: SWOT Analysis of Brazil Pharmaceuticals Market
Table 12‑1: Strengths and Weaknesses of 7 Major Players (Novartis, EMS Pharma, Hypera Pharma, Sanofi, Bayer, Ache Laboratories and Eurofarma) Operating in Brazil Pharmaceuticals Market
Table 12‑2: Market Share of Major Players (Ache Laboratories, EMS Pharma, Eurofarma, Sanofi, Novartis, Neo Quimica, Mantecorp Farmasa, Libbs, Biolab- Sanus Farma, Takeda Pharma, Medley, Bayer Pharma, CIMED, Pfizer and Others) in Brazil Pharmaceuticals Market on the basis of PPP Revenue in USD Million, 2018
Table 12‑3: Market Share of Major Players (Ache Laboratories, EMS Pharma, Eurofarma, Sanofi, Novartis, Neo Quimica, Mantecorp Farmasa, Libbs, Biolab- Sanus Farma, Takeda Pharma, Medley, Bayer Pharma, CIMED, Pfizer and Others) in Brazil Pharmaceuticals Market on the basis of Revenue in PPP USD Million, 2014-2017
Table 12‑4: Cross Comparison of top 7 Players in Brazil Pharmaceuticals Market on the Basis of Year of Establishment, Location, Employee Size, International/Domestic, Business Model and Business Segment, 2018
Table 12‑5: Cross Comparison of top 7 Players in Brazil Pharmaceuticals Market on the Basis of Subsidiaries, Major Specialization, Number of Therapeutic Class and Major Therapeutic Class, 2018
Table 12‑6: Heat Map of All Major Players (Novartis, EMS Pharma, Sanofi, Roche Laboratories, Ache Laboratories, Eurofarma, Bayer, Takeda, Pfizer, Biolab, GSK Pharma, Abbott Laboratories, Janssen Pharmaceuticals and Neo-Quimica) on the Basis of Regional Presence, 2018
Table 12‑7: Heat Map of top 13 players in Brazil Pharmaceuticals Market on the Basis of Therapeutic Areas Including Gastrointestinal, Cardiology, Anti-Infective, Respiratory, Central Nervous System and Dermatology, 2018
Table 12‑8: Heat Map of top 13 players in Brazil Pharmaceuticals Market on the Basis of Therapeutic Areas Including Orthopedics, Oncology, Genitourinary and Sex Hormones, Blood Forming Organs/Hematology, 2018
Table 13‑1: Company Profile of Novartis Including Company Overview, Research and Development, Future Outlook, Manufacturing Plants and Production Matrix
Table 13‑2: Financial Performance of Novartis Group by Business Divisions (Sandoz, Alcon and Innovative Medicines) and by Regions (Europe, United States, Asia, Africa, Australasia, and Canada & Latin America) on the Basis of Revenue in USD Million, 2018
Table 13‑3: Company Profile of EMS Pharma Including Company Overview, Strength, Focus Areas, Business Units and Facts and Figures
Table 13‑4: Company Profile of Hypera Pharma Including Business Units, Business Segments, Research Center, Neo Quimica, Recent Developments (2017), Research and Development and Revenue
Table 13‑5: Distribution Channels of Hypera Pharma by Type (Direct Channel, Indirect Channel and Transfer Order)
Table 13‑6: Financial Performance of Hypera Pharma by Business Segments (RX/OTX, Consumer Health, Generics and Dermocosmetics) on the Basis of Revenue in USD Million, 2018(P)
Table 13‑7: Financial Performance of Hypera Pharma by Therapeutic Areas (RX and Dermocosmetics) on the Basis of Revenue in USD Million, 2018(P)
Table 13‑8: Financial Performance of Hypera Pharma by Therapeutic Areas in Consumer Health (Gastrointestinal, Flu and Cold, Vitamins and Nutraceuticals, Pain and Fever, Orthopedics and Others) on the Basis of Revenue in USD Million, 2018(P)
Table 13‑9: Hypera Pharma Products under Pipeline by Business Segments (Prescription Products, Similar & Generics and Consumer Health) on the Basis of Number of Patents, 2018
Table 13‑10: Company Profile of Sanofi Brazil Including Company Overview, Investment Areas, Growth Areas, Market Share, Business Segment, Major Therapeutic Areas and Future
Table 13‑11: Product Portfolio of Sanofi by Therapeutic Areas (Rare Diseases, Multiple Sclerosis, Immunology, Rare Blood Disorder, Oncology, Diabetes, Cardiovascular, Disease and Established Prescription Products)
Table 13‑12: Company Profile of Bayer Including Company Overview, Business Division, Consumer Health, Pharmaceutical Division, Production Units and Revenue, 2018
Table 13‑13: Major Marketed Products by Bayer in Pharmaceuticals and Consumer Health Segment on the Basis of Application and Core activities and markets, 2018
Table 13‑14: Financial Performance of Bayer in Latin America by Countries (Brazil and Others) on the Basis of Revenue in USD Million, 2017 and 2018
Table 13‑15: Company Profile of Roche Laboratories Including Company Overview, Production Units, Research and Development, Business Segments, Recent Developments and Revenue
Table 13‑16: Company Profile of Ache Laboratories Including Company Overview, Pharmaceutical Segments, Industrial Plant Locations, Portfolio and Brands, Distribution and Point of Sales and Recent Developments
Table 13‑17: Financial Performance of Ache Laboratories on the Basis of Gross Profit and EBITDA in USD Million, 2017-2018
Table 13‑18: Company Profile of Eurofarma Including Company Overview, Therapeutic Areas, Specialties and Retail Sales, Business Segments, Recent Developments, Product Portfolio in Brazil, Subsidiaries, Strategy, Presence and Future Strategy
Table 13‑19: Financial Performance of Eurofarma by Segment on the Basis of Revenue in USD Million, 2017
Table 13‑20: Company Profile of Other Players (Biolab Pharma, Takeda and CIMED) Including Company Overview, Product portfolio, Specialization, Production Plants, Key Focus Areas and Unique Selling Proposition
Table 15‑1: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by International and Domestic Companies on the Basis of Revenue in USD Billion, 2018-2025F
Table 15‑2: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by Retail and Institutional Sales on the Basis of Revenue in USD Billion, 2018-2025F
Table 15‑3: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by Institutional Sales (Public, Private and Others) on the Basis of Revenue in USD Billion, 2018-2025F
Table 15‑4: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by Drug Type (Prescription, Over-The-Counter and Generics) on the Basis of Revenue in USD Billion, 2018-2025F
Table 15‑5: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by Generic Drugs (Branded and Local) on the Basis of Revenue in USD Billion, 2018-2025F
Table 15‑6: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by Therapeutic Areas (Cardiology, Central Nervous System, Respiratory, Oncology, Anti- Infective, Gastrointestinal and Others) on the Basis of Revenue in USD Billion, 2025F
Table 16‑1: Time Required for the Approval of Drugs Registration

Licence Rights

License Type Excel Only Single User Single User + Excel Hard Copy Corporate User License
User Sharing Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only. Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only. Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only. Access to Printed Report; No Soft Copy Multiple Users within the Company/ Enterprise
Print Option
Copy Option :Yes :No
Citation Yes (Not Publically; but to Private Parties within the company/ affiliate)
Deliverable Format :via Email :via Email ; :via Email Printed Publication/ Book by Post ; :via Email
Customization 20%
Analyst Time (Post Purchase Queries on Call/ Email)
Disclaimer : In no circumstance, the complete / part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view.

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Key Segments Covered
By Type of Companies
  • International Companies
  • Domestic Companies
By Type of Channel
  • Institutional
    • Public
    • Private
    • Others
  • Retail
By Drug Type
  • Prescription
  • Over-The-Counter
  • Generics
    • Branded
    • Local
By Region
  • Southeast
  • South
  • Midwest
  • Northeast
  • North
By Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Respiratory
  • Oncology
  • Anti-Infective
  • Gastrointestinal
  • Others
Key Target Audience
  • Pharmaceutical Manufacturing Companies
  • Pharmacy Retail Outlets
  • Government/ Regulatory Authorities
  • Venture Capitalist Firms
  • Health Insurance Companies
  • Pharmaceutical Products Distributors
Time Period Captured in the Report:
  • Historical Period: 2013-2018
  • Forecast Period: 2019F-2025F


Companies

Companies Covered:
Major Manufacturers
  • Ache Laboratories
  • EMS Pharma
  • Eurofarma
  • Sanofi
  • Novartis
  • Neo Quimica
  • Mantecopr Farmasa
  • Libbs
  • Biolab- Sanus Farma
  • Takeda Pharma
  • Medley
  • Bayer Pharma
  • CIMED

The report titled “Brazil Pharmaceuticals Market Outlook to 2025 - By International and Domestic Companies, By Retail and Institutional Sales, By Institutional Sales (Public, Private and Others), By Drug Type (Prescription, Over-The-Counter and Generics), By Generic Drug Type (Branded and Local), By Region (Southeast, South, Northeast, Midwest and North), By Therapeutic Areas” provides a comprehensive analysis of the Pharmaceuticals market in Brazil. The report also covers the overview and genesis, market size in terms of Revenue, trends and developments, issues and challenges and regulations in Brazil. The report provides value chain, competitive scenario and company profiles of the major players operating in Brazil. The report concludes with market projection and analyst recommendations highlighting the major opportunities and cautions.


Brazil Pharmaceuticals Market Overview and Size
Brazil Pharmaceuticals market in terms of revenue increased at a double digit CAGR during the review period 2013-2018. The market was observed to be at growth stage owing to growing intensity of competition among the domestic and international manufacturers in the market which allows them to invest heavily in Research and Development and provides wide offering of patented and generic drugs in Prescription and Over-The-Counter form in the country. In Brazil, the number of growing chronic diseases and per capita healthcare expenditure to spend on the medications will improve the revenues of Pharmaceuticals Market over the years in Brazil.
The market is booming with the Universal Health System, growing elderly population, huge investment in R&D for new drugs, reduced time in the manufacturing approval process, increasing government health expenditure, acquisitions of brands to expand in different regions and segments coupled with per capita income of individuals in Brazil.

Brazil Pharmaceuticals Market Segmentation

By International and Domestic Companies: Brazil is moderately fragmented market with the presence of many International and Domestic players. International Companies dominates the sales volume of patented drugs whereas the domestic companies are largely involved in the production of Generic drugs in terms of sales volume. On the other hand, patented drugs are largely expensive and generate comparatively higher revenues than the generics. Moreover, International companies have strong distribution channel to serve every region in Brazil. Hence, they accounts for a larger share in terms of revenue in Pharmaceuticals Market in Brazil.

By Distribution Channel: Majority of the revenues are generated from the retail segment in Brazil. The highest revenue share of retail sales was largely due to the presence of number of retail outlets in all the areas of Brazil. Institutional sales on the other hand are driven by the new product innovations being largely recommended by physician or the doctor.

By Institutional Sales: Public Institutions in Brazil accounted for the highest percentage share in terms of revenue due to the presence of large number of public hospitals in the country and the Hospitals’ own pharmacies that gives the advantage of prescription and OTC medications to the patients. Private Institutions on the other hand accounted for a lower percentage share due to the decline in the number of private hospitals observed over the years.

By Type of Drugs: Prescription drugs accounted for the highest revenue share in terms in the year 2018. Prescription drugs in the market are generally patented drugs being recommended by the doctors and are usually taken for chronic diseases. These medicines are being served among middle to upper class population in Brazil. Higher prices of these medicines generate higher revenues from prescription drugs segment in the country. OTC and Generic drugs on the other hand are affordable by the majority of the population and serve the underpenetrated areas of the country.

By Region: Southeast region in Brazil that includes Sao Paulo and Rio de Janeiro accounted for highest revenue share in 2018 due to the highest population in Brazil, Highest contribution to GDP, diverse pharmaceutical industry and high purchasing power of in that region. Southeast region is followed by South and Midwest region in Brazil due to the high purchasing power of the individuals in that region.

By Therapeutic Areas: Cardiovascular segment accounts for the highest percentage share in terms of revenue in Brazil largely due the highest number of deaths being caused by Ischemic Heart Disease among all other causes of deaths in Brazil. It is followed by Central Nervous System, Respiratory and Oncology. The manufacturing companies are making oncology as their major product innovation area in Brazil.

Competitive Landscape
Pharmaceuticals Market in Brazil is a moderately fragmented market with presence of domestic and international players wherein the patented drug manufacturers are mainly the international companies and generic drug manufacturers are majorly the domestic ones. Major Domestic Companies include Ache Laboratories, EMS Pharma, Eurofarma and Hypera Pharma and international companies include Novartis, Sanofi, Bayer, Abbott Laboratories and many others.

Brazil Pharmaceuticals Market Future Outlook
In future, it is anticipated that the revenue of Pharmaceuticals Market in Brazil will be driven by the growing elderly population (above 65 years), growing prevalent of chronic diseases, increasing per Capita health expenditure, ease in availability of medicines coupled with growing number of acquisitions to expand business portfolio, increasing number of Point of Sale and rising investment in R&D activities.
Key Segments Covered
By Type of Companies
·         International Companies
·         Domestic Companies
By Type of Channel
·         Institutional
Ø  Public
Ø  Private
Ø  Others
·          Retail
By Drug Type
·         Prescription
·         Over-The-Counter
·         Generics
Ø  Branded
Ø  Local
By Region
·         Southeast
·         South
·         Midwest
·         Northeast
·         North
By Therapeutic Areas
·         Cardiovascular
·         Central Nervous System
·         Respiratory
·         Oncology
·         Anti-Infective
·         Gastrointestinal
·         Others
Key Target Audience
·         Pharmaceutical Manufacturing Companies
·         Pharmacy Retail Outlets
·         Government/ Regulatory Authorities
·         Venture Capitalist Firms
·         Health Insurance Companies
·         Pharmaceutical Products Distributors
Time Period Captured in the Report:
·         Historical Period: 2013-2018
·         Forecast Period: 2019F-2025F
Companies Covered:
Major Manufacturers
  • Ache Laboratories
  • EMS Pharma
  • Eurofarma
  • Sanofi
  • Novartis
  • Neo Quimica
  • Mantecopr Farmasa
  • Libbs
  • Biolab- Sanus Farma
  • Takeda Pharma
  • Medley
  • Bayer Pharma
  • CIMED
Key Topics Covered in the Report
·         Brazil Pharmaceuticals Market Overview and Genesis (Overview and Genesis, Business Cycle Graph)
·         Brazil Pharmaceutical Market Value Chain Analysis
·         Brazil Pharmaceutical Market Size
·         Brazil Pharmaceuticals Market Segmentation
·         Regulatory Landscape in Brazil Pharmaceuticals Market
·         Trends and Developments in Brazil Pharmaceuticals Market
·         Issues and Challenges in Brazil Pharmaceuticals Market
·         Brazil Pharmaceuticals Market Competition Landscape
·         Cross Comparison of 7 Major Players in Brazil Pharmaceuticals Market
·         Brazil Pharmaceuticals Market Future Projection, 2018-2025F
·         Future Outlook of Brazil Pharmaceuticals Market Segmentations, 2018-2025F
READ MORE

Scope

1.     Executive Summary
2.     Research Methodology
2.1.      Market Definitions
2.2.      Abbreviations
2.3.      Market Sizing and Modeling
Consolidated Research Approach
Market Sizing Approach – Brazil Pharmaceuticals Market
Sample Size Inclusion Table
Variables Dependent And Independent
Multi Factor Based Sensitivity Model
Limitations
Final Conclusion
3.     Brazil Pharmaceuticals Market Overview and Genesis
4.     Brazil Pharmaceuticals Market Value Chain Analysis
5.     Brazil Pharmaceuticals Market Size, 2013-2018
5.1.      By Revenue, 2013-2018
6.     Brazil Pharmaceuticals Market Segmentation, 2013 and 2018
6.1.      By International and Domestic Companies, 2013 and 2018
6.2.      By Retail and Institutional, 2013-2018
6.2.1.     By Institutional (Public, Private and Others)
6.2.2.     By Drug Type (Prescription, Over-The-Counter and Generic Drugs), 2018
By Generic Drugs (Branded and Local), 2018
6.2.3.     By Region (Southeast, South, Northeast, Midwest and North), 2018
6.2.4.     By Therapeutic Areas (Cardiovascular, Central Nervous System, Respiratory, Oncology, Anti- Infective, Gastrointestinal and Others), 2018
7.     Brazil Pharmaceuticals Vitamins and Dietary Supplements
8.     Regulatory Landscape in Brazil Pharmaceuticals Market
8.1.      ANVISA (Regulatory Body)
8.2.      Brazil Pharmaceuticals Market Clinical Process
9.     Trends and Developments in Brazil Pharmaceuticals Market
Growing Number of Substitutes for Patented Drugs
Growing Number of mergers and Acquisitions
Government Initiatives to Promote Local Production
Growing Ministry of Health Budget
10.      Issues and Challenges in Brazil Pharmaceuticals Market
Intensified Competition in Local Drug Manufacturers
Economic Instability
Currency Depreciation
11.      SWOT Analysis of Brazil Pharmaceuticals Market
12.      Competitive Landscape in Brazil Pharmaceuticals Market
12.1.    Strengths and Weaknesses of Major Players in Brazil Pharmaceuticals Market
12.2.    Market Share of Major Players (Ache Laboratories, EMS Pharma, Eurofarma, Sanofi, Novartis, Neo Quimica, Mantecorp Farmasa, Libbs, Biolab- Sanus Farma, Takeda Pharma, Medley, Bayer Pharma, CIMED, Pfizer and Others) Operating in Brazil Pharmaceuticals Market, 2018
12.3.    Cross-Comparison of 7 Major Players (Year of Establishment, Location, Employee Size, International/Domestic, Business Model and Business Segment, Subsidiaries, Major Specialization, Number of Therapeutic Class and Major Therapeutic Class)
12.4.    Heat Map Analysis of Top 14 Players (Novartis, EMS Pharma, Sanofi, Roche Laboratories, Ache Laboratories, Eurofarma, Bayer, Takeda, Pfizer, Biolab, GSK Pharma, Abbott Laboratories, Janssen Pharmaceuticals and Neo-Quimica) on Regional Presence (Southeast South, Northeast, Mid West, North), 2018
12.5.    Heat Map Analysis of Top 13 Players (Novartis, EMS Pharma, Sanofi, Roche Laboratories, Ache Laboratories, Eurofarma, Bayer, Takeda, Pfizer, Biolab, GSK Pharma, Abbott Laboratories and Janssen Pharmaceuticals) on the Basis of Therapeutic Areas (Gastrointestinal, Cardiology, Anti-Infective, Respiratory, Central Nervous System and Dermatology, Orthopedics, Oncology, Genitourinary and Sex Hormones, Blood Forming Organs/Hematology), 2018
13.      Company Profile of Major Players (Company Overview, Research and Development, Future Outlook, Manufacturing Plants and Production Matrix)
13.1.    Novartis
13.2.    EMS Pharma
13.3.    Hypera Pharma
13.4.    Sanofi Brazil
13.5.    Bayer
13.6.    Roche Laboratories
13.7.    Ache Laboratories
13.8.    Eurofarma
13.9.    Others (Biolab Pharma, Takeda, Cimed)
14.      Brazil Pharmaceuticals Market Future Outlook and Projections, 2018-2025F
14.1.    By Revenue, 2018-2025F
15.      Brazil Pharmaceuticals Market Segmentation Future Outlook and Projections
15.1.    By International and Domestic Companies, 2018-2025F
15.2.    By Retail and Institutional, 2018-2025F
15.2.1.       By Institutional Sales (Public, Private and Others), 2018-2025F
15.2.2.       By Drug Type (Prescription, Over-The-Counter and Generics)
By Generic Drugs (Branded and Local), 2018-2025F
15.2.3.       By Therapeutic Areas (Cardiology, Central Nervous System, Respiratory, Oncology, Anti- Infective, Gastrointestinal and Others), 2025F
16.      Analyst Recommendation
Investment in R&D
Focus on Improving Productivity
Keeping Track of Expiry Patents
Focus on building a strong product portfolio
Inestment in Marketing Activities
Disclaimer
Contact Us


List Of Figure

Figure 1‑1: Brazil Pharmaceuticals Market Flowchart on the Basis of Revenue in USD Billion, 2018
Figure 1‑2: Brazil Pharmaceuticals Market Flowchart on the Basis of Revenue in USD Billion, 2025F
Figure 3‑1: Brazil Pharmaceuticals Industry Life Cycle
Figure 4‑1: Value Chain of Brazil Pharmaceuticals Market
Figure 5‑1: Brazil Pharmaceuticals Market Size of on the Basis of Revenue in USD Billion and Growth Rate in Percentage (%), 2013-2018
Figure 6‑1: Brazil Pharmaceuticals Market Segmentation by Type of Companies (International and Domestic) on the Basis of Revenue in Percentage (%), 2013 and 2018
Figure 6‑2: Brazil Pharmaceuticals Market Segmentation by Retail and Institutional on the Basis of Revenue in Percentage (%), 2013-2018
Figure 6‑3: Brazil Pharmaceuticals Market Segmentation by Institutional (Public, Private and Others) on the Basis of Revenue in Percentage (%), 2013-2018
Figure 6‑4: Number of Hospitals in Brazil by Type (Public and Private), 2013-2018
Figure 6‑5: Brazil Pharmaceuticals Market Segmentation by Drugs (Prescription, Over-The-Counter and Generics) on the Basis of Revenue in Percentage (%), 2018
Figure 6‑6: Brazil Pharmaceuticals Market Segmentation by Type of Generic Drugs (Branded and Local) on the Basis of Revenue in Percentage (%), 2018
Figure 6‑7: Brazil Pharmaceuticals Market Segmentation by Regions (Southeast, South, Northeast, Midwest and North) on the Basis of Revenue in Percentage (%), 2018
Figure 6‑8: Brazil Pharmaceuticals Market Segmentation by Therapeutic Areas (Cardiovascular, Central Nervous System, Respiratory, Oncology, Anti-Infective, Gastrointestinal and Others) on the Basis of Revenue in Percentage (%), 2018
Figure 7‑1: Brazil Vitamins and Dietary Supplements Market Segmentation by Outlet Type (Store-Based Retailing and Non-Store Retailing) on the Basis of Revenue in Percentage (%), 2013-2019P
Figure 7‑2: Brazil Vitamins and Dietary Supplements Market Segmentation by Type (Herbal/Traditional and Standard) on the Basis of Revenue in Percentage (%), 2013-2019P
Figure 8‑1: Clinical Process in Brazil Pharmaceuticals Market
Figure 9‑1: Brazil Pharmaceuticals Market Major Acquisitions on the Basis of Number and Total Deal Value in USD Million, 2007-2016
Figure 9‑2: Ministry of Health Budget in Brazil Including Pharmaceuticals Assistance Activities and Other Ministry of Health Activities in Percentage (%), 2012-2019P
Figure 10‑1: Exchange Rate (BRL-USD), 2013-2018
Figure 12‑1: Market Share of Major Players (Ache Laboratories, EMS Pharma, Eurofarma, Sanofi, Novartis, Neo Quimica, Mantecorp Farmasa, Libbs, Biolab- Sanus Farma, Takeda Pharma, Medley, Bayer Pharma, CIMED, Pfizer and Others) in Brazil Pharmaceuticals Market on the Basis of Revenue in Percentage (%), 2018
Figure 13‑1: Financial Performance of Novartis Group by Business Divisions (Sandoz, Innovative Medicines and Alcon) and by Regions (Europe, United States, Asia, Africa, Australasia, and Canada & Latin America) on the Basis of Revenue in Percentage(%), 2018
Figure 13‑2: Timeline of Hypera Pharma from 2007 to 2017
Figure 13‑3: Distribution Channel of Hypera Pharma including Direct Channel and Indirect Channel on the Basis of Revenue in Percentage (%), 2018(P)
Figure 13‑4: Financial Performance of Hypera Pharma by Business Segments (RX/OTX, Consumer Health, Generics and Dermocosmetics) on the Basis of Revenue in Percentage (%), 2018(P)
Figure 13‑5: Financial Performance of Hypera Pharma by Therapeutic Areas (RX and Dermocosmetics) on the Basis of Revenue in Percentage (%), 2018(P)
Figure 13‑6: Financial Performance of Hypera Pharma by Therapeutic Areas in Consumer Health (Gastrointestinal, Flu and Cold, Vitamins and Nutraceuticals, Pain and Fever, Orthopedics and Others) on the Basis of Revenue in Percentage (%), 2018(P)
Figure 13‑7: Hypera Pharma Products under Pipeline by Business Segments (Prescription Products, Similar & Generics and Consumer Health) on the Basis of Number of Patents in Percentage (%), 2018
Figure 13‑8: Hypera Pharma Products under Pipeline by Innovation (White Spaces, New Technologies, New Formulation and Patented) in Percentage (%), 2018
Figure 13‑9: Hypera Pharma Prescription Products under Pipeline by Therapeutic Areas (General Physician, Central Nervous System, Pain/Pain Killers, Allergy/ Respiratory/ Ear, Cardiovascular & Endocrinology, Gastro Intestinal and Dermocosmetics) in Percentage (%), 2018
Figure 13‑10: Financial Performance of Hypera Pharma on the Basis of Revenue in USD Million, 2015-2018(P)
Figure 13‑11: Financial Performance of Hypera Pharma on the Basis of EBITDA in USD Million, 2015-2018(P)
Figure 13‑12: Financial Performance of Hypera Pharma on the Basis of Gross Profit in USD Million, 2015-2018(P)
Figure 13‑13: Timeline of Sanofi Brazil from 1919 to 2017
Figure 13‑14: Financial Performance of Sanofi in Brazil on the Basis of Revenue in USD Million, 2017-2018
Figure 13‑15: Financial Performance of Bayer in Latin America by Countries (Brazil and Others) on the Basis of Revenue in Percentage (%), 2017 and 2018
Figure 13‑16: Financial Performance of Roche Laboratories on the Basis of Revenue in USD Million, 2017-2018
Figure 13‑17: Ache Laboratories products under pipeline by Franchise (Prescription, Dermatology, OTC, Generics and Specialty Care) on the Basis of Number of Patents, 2013-2022
Figure 13‑18: Financial Performance of Ache Laboratories on the Basis of Revenue in USD Million, 2017-2018
Figure 13‑19: Financial Performance of Ache Laboratories by Therapeutic Areas (Breathing Apparatus, Nervous System, Cardiovascular, Digestive Track and Metabolism, Musculoskeletal System, Endocrine System including Sex Hormones, Dermatology, Genitourinary Systems and Others) on the Basis of Revenue in Percentage (%), 2018
Figure 13‑20: Timeline of Ache Laboratories from the Year 1966 to 2018
Figure 13‑21: Financial Performance of Eurofarma on the Basis of Revenue in USD Million, 2016 and 2017
Figure 13‑22: Financial Performance of Eurofarma on the Basis of Gross Profit in USD Million, 2016 and 2017
Figure 13‑23: Financial Performance of Eurofarma on the Basis of EBITDA in USD Million, 2016 and 2017
Figure 13‑24: Financial Performance of Eurofarma by Segment on the Basis of Revenue in Percentage (%), 2017
Figure 13‑25: Timeline of Eurofarma Laboratories Brazil from 1972 to 2018
Figure 14‑1: Brazil Pharmaceuticals Future Projections on the Basis of Revenue in USD Billion and Growth Rate in Percentage (%), 2018-2025F
Figure 15‑1: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by International and Domestic Companies on the Basis of Revenue in Percentage (%), 2018-2025F
Figure 15‑2: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by Retail and Institutional Sales on the Basis of Revenue in Percentage (%), 2018-2025F
Figure 15‑3: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by Institutional Sales (Public, Private and Others) on the Basis of Revenue in Percentage (%), 2018-2025F
Figure 15‑4: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by Drug Type (Prescription, Over-The-Counter and Generics) on the Basis of Revenue in Percentage (%), 2018-2025F
Figure 15‑5: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by Generic Drugs (Branded and Local) on the Basis of Revenue in Percentage (%), 2018-2025F
Figure 15‑6: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by Therapeutic Areas (Cardiology, Central Nervous System, Respiratory, Oncology, Anti- Infective, Gastrointestinal and Others) on the Basis of Revenue in Percentage (%), 2025F


List Of Table

Table 2‑1: Consolidated Research Approach for Sample Market
Table 2‑2: Sample Size Including Major Players in Brazil Pharmaceuticals Market and Industry Experts
Table 2‑3: Sample Size Inclusion Table Including Respondent Category and Percentage of Sample Size
Table 2‑4: Tentative Set of Questions Asked by Mode of Entities and Desired Outcome
Table 2‑5: Correlation Matrix of Brazil Pharmaceuticals Market
Table 2‑6: Regression Coefficients Outputs of Brazil Pharmaceuticals Market
Table 5‑1: List of Countries Including Number of Patents, 2017
Table 6‑1: Cross Comparison of International and Domestic Companies on the Basis of Revenue Share in terms of Percentage, Major Companies, Regional Presence, Key Focus Area, Specialization, Number of Companies and Growth Drivers
Table 6‑2: Brazil Pharmaceuticals Market Segmentation by Type of Companies (International and Domestic) on the Basis of Revenue in USD Billion, 2013 and 2018
Table 6‑3: Cross Comparison of Retail and Institutional on the Basis of Revenue Share in terms of Percentage (%), Profit Margin, Growth Drivers, Target Audience and Major Drugs
Table 6‑4: Brazil Pharmaceuticals Market Segmentation by Retail and Institutional on the Basis of Revenue in USD Billion, 2013-2018
Table 6‑5: Brazil Pharmaceuticals Market Segmentation by Institutional (Public, Private and Others) on the Basis of Revenue in USD Billion, 2013-2018
Table 6‑6: Number of Hospitals in Brazil by Type (Public and Private), 2013-2018
Table 6‑7: Cross Comparison of Prescription, Over-The-Counter and Generic Drugs on the Basis of Revenue Share in terms of Percentage, Major Companies, Rationale, Target Audience, R&D Costs and Price Difference
Table 6‑8: Brazil Pharmaceuticals Market Segmentation by Drugs (Prescription, Over-The-Counter and Generics) on the Basis of Revenue in USD Billion, 2018
Table 6‑9: Brazil Pharmaceuticals Market Segmentation by Type of Generic Drugs (Branded and Local) on the Basis of Revenue in USD Billion, 2018
Table 6‑10: Cross Comparison by Regions (Southeast, South, Northeast, Midwest and North) including Population, Market Share, Major Cities, Concentration of Companies, GDP Contribution, Economy, Key Performance Indicators and Major Companies
Table 6‑11: Brazil Pharmaceuticals Market Segmentation by Regions (Southeast, South, Northeast, Midwest and North) on the Basis of Revenue in USD Billion, 2018
Table 6‑12: Brazil Pharmaceuticals Market Segmentation by Therapeutic Areas (Cardiovascular, Central Nervous System, Respiratory, Oncology, Anti-Infective, Gastrointestinal and Others) on the Basis of Revenue in USD Billion, 2018
Table 6‑13: Brazil Pharmaceuticals Market Segmentation by Therapeutic Areas (Cardiovascular, Central Nervous System, Respiratory, Oncology, Anti-Infective, Gastrointestinal and Others) on the Basis of Best Selling Medicines, Major Companies and OTC/ Prescribed
Table 7‑1: Brazil Vitamins and Dietary Supplements Snapshot including Market Size, Competition Scenario, Trends and Developments and Major Brands, 2013-2018
Table 7‑2: Brazil Vitamins and Dietary Supplements Market Size on the Basis of Revenue in USD Million and Growth Rate in Percentage (%), 2013-2024F
Table 7‑3: Market Share of Major Players operating in Brazil Vitamins and Dietary Supplements Market on the Basis of Revenue in Percentage (%), 2013-2019P
Table 7‑4: Market Share of Major Players operating in Brazil Vitamins and Dietary Supplements Market on the Basis of Revenue in USD Million, 2013-2019P
Table 7‑5: Market Share of Major Brands Including Major Companies operating in Brazil Vitamins and Dietary Supplements Market on the Basis of Revenue in Percentage (%), 2013-2019P
Table 7‑6: Market Share of Major Brands Including Major Companies operating in Brazil Vitamins and Dietary Supplements Market on the Basis of Revenue in USD Million, 2013-2019P
Table 7‑7: Brazil Vitamins and Dietary Supplements Market Segmentation by Outlet Type (Store-Based Retailing and Non-Store Retailing) on the Basis of Revenue in USD Million, 2013-2019P
Table 7‑8: Brazil Vitamins and Dietary Supplements Market Segmentation by Type (Herbal/Traditional and Standard) on the Basis of Revenue in USD Million, 2013-2019P
Table 8‑1: Government Regulations in Brazil Pharmaceutical Market Including Regulatory Submission of Drug Application, Pricing, Requirements for Price Approval, Access to Drugs, Operating Authorization, Operating License, Product Registration, Technical Responsibility Certificate, Pharmacovigilance, Techno vigilance, Promotion and Marketing and Pre-Conditions for Distribution, 2018
Table 8‑2: Registration and Licensing Requirements in Pharmaceuticals Market in Brazil
Table 9‑1: Major Acquisitions in Brazil Pharmaceuticals Market, 2012-2018
Table 9‑2: Ministry of Health Budget in Brazil Including Pharmaceuticals Assistance Activities and Other Ministry of Health Activities in USD Million, 2012-2019P
Table 9‑3: Pharmaceuticals Assistance Budget in Brazil in USD Million, 2012-2019P
Table 11‑1: SWOT Analysis of Brazil Pharmaceuticals Market
Table 12‑1: Strengths and Weaknesses of 7 Major Players (Novartis, EMS Pharma, Hypera Pharma, Sanofi, Bayer, Ache Laboratories and Eurofarma) Operating in Brazil Pharmaceuticals Market
Table 12‑2: Market Share of Major Players (Ache Laboratories, EMS Pharma, Eurofarma, Sanofi, Novartis, Neo Quimica, Mantecorp Farmasa, Libbs, Biolab- Sanus Farma, Takeda Pharma, Medley, Bayer Pharma, CIMED, Pfizer and Others) in Brazil Pharmaceuticals Market on the basis of PPP Revenue in USD Million, 2018
Table 12‑3: Market Share of Major Players (Ache Laboratories, EMS Pharma, Eurofarma, Sanofi, Novartis, Neo Quimica, Mantecorp Farmasa, Libbs, Biolab- Sanus Farma, Takeda Pharma, Medley, Bayer Pharma, CIMED, Pfizer and Others) in Brazil Pharmaceuticals Market on the basis of Revenue in PPP USD Million, 2014-2017
Table 12‑4: Cross Comparison of top 7 Players in Brazil Pharmaceuticals Market on the Basis of Year of Establishment, Location, Employee Size, International/Domestic, Business Model and Business Segment, 2018
Table 12‑5: Cross Comparison of top 7 Players in Brazil Pharmaceuticals Market on the Basis of Subsidiaries, Major Specialization, Number of Therapeutic Class and Major Therapeutic Class, 2018
Table 12‑6: Heat Map of All Major Players (Novartis, EMS Pharma, Sanofi, Roche Laboratories, Ache Laboratories, Eurofarma, Bayer, Takeda, Pfizer, Biolab, GSK Pharma, Abbott Laboratories, Janssen Pharmaceuticals and Neo-Quimica) on the Basis of Regional Presence, 2018
Table 12‑7: Heat Map of top 13 players in Brazil Pharmaceuticals Market on the Basis of Therapeutic Areas Including Gastrointestinal, Cardiology, Anti-Infective, Respiratory, Central Nervous System and Dermatology, 2018
Table 12‑8: Heat Map of top 13 players in Brazil Pharmaceuticals Market on the Basis of Therapeutic Areas Including Orthopedics, Oncology, Genitourinary and Sex Hormones, Blood Forming Organs/Hematology, 2018
Table 13‑1: Company Profile of Novartis Including Company Overview, Research and Development, Future Outlook, Manufacturing Plants and Production Matrix
Table 13‑2: Financial Performance of Novartis Group by Business Divisions (Sandoz, Alcon and Innovative Medicines) and by Regions (Europe, United States, Asia, Africa, Australasia, and Canada & Latin America) on the Basis of Revenue in USD Million, 2018
Table 13‑3: Company Profile of EMS Pharma Including Company Overview, Strength, Focus Areas, Business Units and Facts and Figures
Table 13‑4: Company Profile of Hypera Pharma Including Business Units, Business Segments, Research Center, Neo Quimica, Recent Developments (2017), Research and Development and Revenue
Table 13‑5: Distribution Channels of Hypera Pharma by Type (Direct Channel, Indirect Channel and Transfer Order)
Table 13‑6: Financial Performance of Hypera Pharma by Business Segments (RX/OTX, Consumer Health, Generics and Dermocosmetics) on the Basis of Revenue in USD Million, 2018(P)
Table 13‑7: Financial Performance of Hypera Pharma by Therapeutic Areas (RX and Dermocosmetics) on the Basis of Revenue in USD Million, 2018(P)
Table 13‑8: Financial Performance of Hypera Pharma by Therapeutic Areas in Consumer Health (Gastrointestinal, Flu and Cold, Vitamins and Nutraceuticals, Pain and Fever, Orthopedics and Others) on the Basis of Revenue in USD Million, 2018(P)
Table 13‑9: Hypera Pharma Products under Pipeline by Business Segments (Prescription Products, Similar & Generics and Consumer Health) on the Basis of Number of Patents, 2018
Table 13‑10: Company Profile of Sanofi Brazil Including Company Overview, Investment Areas, Growth Areas, Market Share, Business Segment, Major Therapeutic Areas and Future
Table 13‑11: Product Portfolio of Sanofi by Therapeutic Areas (Rare Diseases, Multiple Sclerosis, Immunology, Rare Blood Disorder, Oncology, Diabetes, Cardiovascular, Disease and Established Prescription Products)
Table 13‑12: Company Profile of Bayer Including Company Overview, Business Division, Consumer Health, Pharmaceutical Division, Production Units and Revenue, 2018
Table 13‑13: Major Marketed Products by Bayer in Pharmaceuticals and Consumer Health Segment on the Basis of Application and Core activities and markets, 2018
Table 13‑14: Financial Performance of Bayer in Latin America by Countries (Brazil and Others) on the Basis of Revenue in USD Million, 2017 and 2018
Table 13‑15: Company Profile of Roche Laboratories Including Company Overview, Production Units, Research and Development, Business Segments, Recent Developments and Revenue
Table 13‑16: Company Profile of Ache Laboratories Including Company Overview, Pharmaceutical Segments, Industrial Plant Locations, Portfolio and Brands, Distribution and Point of Sales and Recent Developments
Table 13‑17: Financial Performance of Ache Laboratories on the Basis of Gross Profit and EBITDA in USD Million, 2017-2018
Table 13‑18: Company Profile of Eurofarma Including Company Overview, Therapeutic Areas, Specialties and Retail Sales, Business Segments, Recent Developments, Product Portfolio in Brazil, Subsidiaries, Strategy, Presence and Future Strategy
Table 13‑19: Financial Performance of Eurofarma by Segment on the Basis of Revenue in USD Million, 2017
Table 13‑20: Company Profile of Other Players (Biolab Pharma, Takeda and CIMED) Including Company Overview, Product portfolio, Specialization, Production Plants, Key Focus Areas and Unique Selling Proposition
Table 15‑1: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by International and Domestic Companies on the Basis of Revenue in USD Billion, 2018-2025F
Table 15‑2: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by Retail and Institutional Sales on the Basis of Revenue in USD Billion, 2018-2025F
Table 15‑3: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by Institutional Sales (Public, Private and Others) on the Basis of Revenue in USD Billion, 2018-2025F
Table 15‑4: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by Drug Type (Prescription, Over-The-Counter and Generics) on the Basis of Revenue in USD Billion, 2018-2025F
Table 15‑5: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by Generic Drugs (Branded and Local) on the Basis of Revenue in USD Billion, 2018-2025F
Table 15‑6: Future Outlook and Projections of Brazil Pharmaceuticals Market Segmentation by Therapeutic Areas (Cardiology, Central Nervous System, Respiratory, Oncology, Anti- Infective, Gastrointestinal and Others) on the Basis of Revenue in USD Billion, 2025F
Table 16‑1: Time Required for the Approval of Drugs Registration

License Type Excel Only Single User Single User + Excel Hard Copy Corporate User License
User Sharing Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only. Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only. Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only. Access to Printed Report; No Soft Copy Multiple Users within the Company/ Enterprise
Print Option
Copy Option :Yes :No
Citation Yes (Not Publically; but to Private Parties within the company/ affiliate)
Deliverable Format :via Email :via Email ; :via Email Printed Publication/ Book by Post ; :via Email
Customization 20%
Analyst Time (Post Purchase Queries on Call/ Email)
Disclaimer : In no circumstance, the complete / part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view.
To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Key Segments Covered
By Type of Companies
  • International Companies
  • Domestic Companies
By Type of Channel
  • Institutional
    • Public
    • Private
    • Others
  • Retail
By Drug Type
  • Prescription
  • Over-The-Counter
  • Generics
    • Branded
    • Local
By Region
  • Southeast
  • South
  • Midwest
  • Northeast
  • North
By Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Respiratory
  • Oncology
  • Anti-Infective
  • Gastrointestinal
  • Others
Key Target Audience
  • Pharmaceutical Manufacturing Companies
  • Pharmacy Retail Outlets
  • Government/ Regulatory Authorities
  • Venture Capitalist Firms
  • Health Insurance Companies
  • Pharmaceutical Products Distributors
Time Period Captured in the Report:
  • Historical Period: 2013-2018
  • Forecast Period: 2019F-2025F


Companies

Companies Covered:
Major Manufacturers
  • Ache Laboratories
  • EMS Pharma
  • Eurofarma
  • Sanofi
  • Novartis
  • Neo Quimica
  • Mantecopr Farmasa
  • Libbs
  • Biolab- Sanus Farma
  • Takeda Pharma
  • Medley
  • Bayer Pharma
  • CIMED